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Structured Abstract: 
Objective: Compare arthroscopic hip surgery with physiotherapy and activity modification for improving 
patient reported outcome measures in patients with symptomatic femoroacetabular impingement (FAI). 
Design: Two-group parallel, assessor-blinded, pragmatic randomised controlled study. 
Setting: Secondary and tertiary care centres across seven NHS England sites. 
Participants: 222 participants aged 18 to 60 years with symptomatic FAI confirmed clinically and 
radiologically were randomised (1:1) to receive arthroscopic hip surgery (n = 112) or physiotherapy and 
activity modification (n = 110). Exclusion criteria included previous surgery, completion of a 
physiotherapy programme targeting FAI within the preceding 12 months, established osteoarthritis 
(Kellgren-Lawrence ≥2), and hip dysplasia (centre-edge angle <20 degrees). 
Intervention: Participants in the physiotherapy group received a goal-based programme tailored to 
individual patient needs with emphasis on improving core stability and movement control. Up to eight 
physiotherapy sessions were delivered over five months. Participants in the arthroscopic hip surgery 
group received surgery to excise the bone that impinged during hip movements, followed by routine 
post-operative care. 
Main Outcome Measures: The primary outcome measure was the Hip Outcome Score Activities of Daily 
Living (HOS ADL) at eight months post randomisation with a minimum clinically importance difference 
between groups of nine points. Secondary outcome measures included additional patient reported 
outcome measures and clinical assessment. 
Results: At eight months post-randomisation, data was available for 100 patients in the arthroscopic hip 
surgery group (89%) and 88 patients in the physiotherapy and activity modification group (80%). Mean 
HOS ADL was 78.4 (95% CI 74.4 to 82.3) for patients randomised to arthroscopic hip surgery and 69.2 
(95% CI 65.2 to 73.3) for patients randomised to physiotherapy and activity modification. Adjusting for 
baseline HOS ADL, age, gender, and study site, mean HOS ADL was 10.0 points higher in the arthroscopic 
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hip surgery group compared with the physiotherapy and activity modification group (95% CI 6.4 to 13.6, 
p<0.001)). No serious adverse events were reported in either group. 
Conclusions: Patients with symptomatic FAI referred to secondary or tertiary care achieve superior 
outcomes with arthroscopic hip surgery compared with non-operative measures. 
Trial Registration: ClinicalTrials.gov identifier: NCT01893034. 
Feasibility Study: 
https://www.ncbi.nlm.nih.gov/pubmed/23610700 
Protocol: 
https://www.ncbi.nlm.nih.gov/pubmed/25431439 
Ethics Approval: 
The trial protocol was approved by Health Research Authority, National Research Ethics Services 
Committee South Central – Berkshire (REC reference: 13/SC/0154) and local research and development 
departments at each participating site. 
Funding: 
Arthritis Research UK and the National Institute for Health Research (NIHR) Oxford Biomedical Research 
Centre (BRC). 
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What This Paper Adds: 
What is already known on this subject: 
• Femoroacetabular Impingement (FAI) describes pathological abutment of the femoral neck 
against the acetabular rim due to morphological abnormalities of the hip. The condition can 
cause pain (FAI syndrome) and is thought to be responsible for half of all hip osteoarthritis. 
 
• The treatment of FAI remains controversial. Physiotherapy and arthroscopic surgery both 
demonstrate the ability to improve symptoms arising from this condition. It remains uncertain 
whether one treatment is superior to the other. 
 
• Despite the absence of evidence to support the use of arthroscopic hip surgery over non-
operative measures, there has been a rapid increase in the number of arthroscopic hip 
procedures performed each year in the UK and abroad. There is also significant regional variation 
in practice. 
 
What this study adds: 
• This study suggests that arthroscopic hip surgery is superior to physiotherapy and activity 
modification at improving patient reported outcome measures in patients referred to secondary 
or tertiary care with FAI syndrome. 
 
• Not all patients benefit from surgery and the decision to operate must follow a detailed 
discussion between the patient and surgeon with specialist expertise in arthroscopic hip surgery. 
 
• The results inform management decisions made by patients, clinicians, and policymakers. 
Further research is required to identify which patients are most likely to benefit from 
intervention, whether treatment is cost-effective, and if arthroscopic surgery remains superior in 
the long-term. 
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Introduction: 
 
Femoroacetabular Impingement (FAI) is a hip condition where adverse morphology predisposes to 
premature joint degeneration(1, 2). This adverse morphology is classified as ‘cam’, ‘pincer’, or ‘mixed’. 
Cam morphology describes a loss of sphericity of the femoral head, pincer morphology describes an 
acetabulum with excessive coverage of the femoral head, whereas mixed describes a combination of the 
two deformities (Figure 1). These hip shapes can cause the femoral neck to impact against the acetabular 
rim during a functional range of movement with resultant damage to the labrum (which is attached to 
the rim), delamination of the adjacent acetabular cartilage and over time, secondary osteoarthritis(1, 3). 
The prevalence of FAI morphology is high and is observed in approximately one fifth of the general 
population(4). Less than 25% of these individuals develop pain(5) (FAI syndrome) or osteoarthritis(1), 
although up to one half of all hip osteoarthritis may develop secondary to FAI(2). Identifying individuals at 
greatest risk of developing joint pathology secondary to FAI remains a challenge. 
Physiotherapy and activity modification represents the principal treatment for symptomatic FAI, 
however, arthroscopic surgery is increasingly adopted to reshape the hip and address damage to the 
labrum and cartilage (Figure 2). The primary treatment goal is to improve pain and function, but 
interventions that modify contact between the femoral neck and acetabular rim may subsequently 
reduce cartilage and joint damage, the risk of osteoarthritis, and need for future hip arthroplasty(6). 
Arthroscopic hip surgery has been shown to be safe(7) but evidence of efficacy is limited. Two 
randomised controlled trials have been performed comparing physiotherapy rehabilitation with 
arthroscopy for improving symptoms: One concluded that there was no difference between 
treatments(8), and the other concluded arthroscopic surgery was superior to best conservative care. 
Despite the limited evidence, arthroscopic hip surgery has become an established treatment with over 
50,000 arthroscopic hip procedures estimated to take place in the United States of America annually(9). 
The number of procedures performed annually in England between 2002 and 2013 increased by 
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727%(10). There is significant regional variation in the number of procedures performed that may reflect 
surgeon preferences or local commissioning of services(10). 
The aim of the Femoroacetabular Impingement Trial (FAIT) is to compare arthroscopic hip surgery with 
physiotherapy and activity modification in patients referred to secondary or tertiary care with 
symptomatic FAI(11). In this manuscript, we report the primary end-point of patient-reported outcomes 
at eight months post-randomisation. Cost-effectiveness and osteoarthritis development will be evaluated 
at three-year follow-up. Study design was based on a prior feasibility study that demonstrated surgeons 
and patients both have equipoise with respect to physiotherapy and activity modification versus 
arthroscopic hip surgery(12).  
  
8 
 
Methods: 
The study was performed as per the published protocol(11). 
Study Design: 
FAIT is a two-group parallel assessor-blinded pragmatic randomised controlled study with 1:1 allocation.  
Participants: 
Eligible participants were aged 18 to 60 years and referred to secondary or tertiary care with 
symptomatic FAI confirmed clinically and with imaging (radiography and magnetic resonance imaging). 
No quantitative imaging measurements were used as inclusion criteria for this study due to the absence 
of agreed diagnostic thresholds and to improve generalisability of study findings(13). Instead, surgeons 
made a qualitative assessment of hip morphology to diagnose FAI. Participants were excluded if they had 
completed a programme of physiotherapy targeting FAI within the preceding 12 months or received 
previous surgery to their symptomatic hip. Additional exclusion criteria were established osteoarthritis 
(Kellgren-Lawrence ≥2) or hip dysplasia (centre-edge angle <20 degrees on anteroposterior pelvis 
radiograph). 
Recruiting Centres: 
Participants were recruited by Consultant Orthopaedic Surgeons from seven NHS sites across England: 
Oxford University Hospitals NHS Foundation Trust, Royal Berkshire NHS Foundation Trust, Harrogate and 
District NHS Foundation Trust, Cambridge University Hospital NHS Foundation Trust, Wye Valley NHS 
Trust, Great Western Hospital NHS Foundation Trust, and Weston Area Health NHS Trust. Study 
participation required that sites were specialist centres that perform a high volume of arthroscopic hip 
procedures and could deliver the goal-based physiotherapy programme.  
Randomisation and masking: 
Randomisation was performed by a research nurse at each site using an automated computer-generated 
telephone randomisation system provided by OCTRU (Oxford Clinical Trials Research Unit). 
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Randomisation for the first 12 participants (10% of original sample size) was based on a simple random 
list and subsequent participants were randomised using a minimisation algorithm. This algorithm 
included a random element (80%) and aimed to generate balanced treatment allocations by age (< 40 or 
≥ 40 years), gender, baseline Activities of Daily Living subscale of the Hip Outcome Score (HOS ADL) 
(<65% or ≥65%), and study site(11).  
Masking of patients and clinicians delivering the intervention was not possible. However, clinicians 
performing follow-up clinical assessments (hip range of movement, strength tests and impingement 
tests) were blinded to the treatment group. Participants were asked not to disclose their treatment and 
were requested to wear shorts to cover any scars. Data entry was performed by staff members 
independent of the study team. 
Interventions (full details in published protocol)12: 
Physiotherapy and Activity Modification (subsequently referred to as ‘Physiotherapy’): There is no agreed 
standardised physiotherapy regime for FAI and a goal-based programme was developed for this trial 
based on the consensus opinion of the study team and existing literature(14). Treatment standardisation 
was achieved by disseminating the study protocol and providing training sessions for participating 
physiotherapists. Physiotherapy compliance and attainment of goals within the prescribed treatment 
themes was recorded by the treating therapist. Treatment was delivered by a Specialist Physiotherapist 
(Band 6) or Advanced Physiotherapy Practitioner (Band 7/8) (Table S1). The programme was tailored to 
individual patient needs and their desired level of function with an emphasis on muscle strengthening to 
improve core stability and movement control. Participants were encouraged to avoid impingement 
positions (extremes of hip flexion, abduction, internal rotation). Up to eight sessions were provided over 
a five-month period to reflect what is feasible in current NHS practice. 
Arthroscopic Surgery: Participating surgeons met prior to trial recruitment to ensure standardisation of 
technique for the study by consensus agreement. Femoral and acetabular bone seen to impinge intra-
operatively was excised with a burr (osteochondroplasty) to eliminate impingement on dynamic hip 
flexion and internal rotation. Labral tears were repaired if possible, or otherwise debrided. Articular 
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cartilage lesions were debrided to a stable base and in areas of full thickness cartilage loss, microfracture 
of the subchondral bone was performed. Participants received post-operative physiotherapy, provided as 
routine care in the NHS, that focused on maintaining range of movement and a graduated return to 
activity. 
Outcomes: 
The primary outcome measure was the HOS ADL measured eight months post randomisation. The HOS 
ADL is a validated patient-reported outcome measure (PROM) for patients undergoing arthroscopic hip 
procedures(15). The HOS ADL ranges from 0 to 100 with higher values indicating better outcomes. 
Additional PROMs were collected as secondary outcome measures to evaluate symptoms: HOS Sport 
subscale(15), Non-Arthritic Hip Score (NAHS)(16), Copenhagen Hip And Groin Outcome Score 
(HAGOS)(17), Oxford Hip Score (OHS)(18), and International Hip Outcome Tool (iHOT-33)(19). Quality of 
life, nature and location of pain, and psychological factors were evaluated using EQ-5D-3L(20), 
PainDETECT(21), and Hospital Anxiety and Depression Score (HADS)(22) respectively. Clinical assessment 
to examine hip range of movements, strength and impingement tests were carried out at baseline and 
follow up visits. At baseline, patients were also asked to complete an ‘expectation’ HOS ADL score to 
indicate the symptoms they expect to experience after treatment is complete. 
Imaging measurements were performed using custom software by academic orthopaedic clinicians (AJRP 
and SF). Osteoarthritis was evaluated as the Kellgren-Lawrence Grade(23). Dysplasia and pincer 
morphology were quantified using the centre edge angle on a standing anteroposterior radiograph. Cam 
morphology was measured as the maximal cartilage alpha angle at the 12 o’clock, 1 o’clock, 2 o’clock, 
and 3 o’clock position on MRI radial slices(24). All Intraclass Correlation Coefficients for intra-observer 
and inter-observer reproducibility values exceeded 0.90 (Figure S1). 
Participants will be followed-up for three years to evaluate the development of osteoarthritis in this 
cohort. Additional outcomes for the long-term analysis include compositional MRI (T2 mapping), serum 
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and urinary biomarkers of osteoarthritis, and health economic data(11). These outcomes are not 
reported in this manuscript. 
Study Assessments: 
The primary and secondary outcome measures were collected at baseline and eight months after 
randomisation, equating to approximately six months after intervention when taking into account the 
waiting times for treatment. This time-point was chosen as i) a clinically meaningful difference of nine 
points in the ADL HOS is detectable six months after arthroscopic hip surgery(15, 25) ii) our feasibility 
study demonstrated that 94% patients were willing to pursue a treatment of six months, but no longer, 
without improvement in their symptoms(12). Postal PROM questionnaires were also included at five 
months post randomisation to capture short-term fluctuations in symptoms. 
If treatment commenced more than 12 weeks post randomisation, follow-up assessments were 
performed six months post intervention rather than eight months post randomisation to ensure the 
schedule remained aligned with routine clinical care. PROMs were collected at eight months post 
randomisation (primary outcome measure) and six months post intervention in this group. 
Sample Size: 
Sample size was based on the primary outcome measure, HOS ADL at eight months post randomisation, 
and was calculated using a minimum clinically important difference between groups of nine points(15). 
Standard deviation was estimated as 14 points, however, summaries presented at a planned interim data 
monitoring meeting demonstrated that the standard deviation was 18 points. A revised calculation 
(significance level 5%, power 90%, loss to follow-up 20%) gave a sample size of 214 (107 participants in 
each group). The sample size increase from 120 to 214 participants was approved by the data monitoring 
committee (DMC). 
Statistical Analysis: 
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The statistical analysis plan was finalised before unblinding the data to study investigators. Statistical 
testing was performed at the two-sided 5% significance level and conducted using STATA 14.2 (StataCorp 
LLC, College Station, TX, USA). Analysis of the primary endpoint and all secondary endpoints was as per 
modified intention to treat (mITT) including patients with available outcome data based on their 
randomised treatment allocation, regardless of compliance. Linear regression analysis was used to 
compare the HOS ADL outcomes at eight months post randomisation between the treatment groups, 
adjusting for the minimisation factors gender, age, baseline HOS ADL, and site. Results were presented as 
treatment effects with 95% confidence intervals and p-values. 
In addition to HOS ADL evaluation within the cohort, it was also assessed within the individual and 
expressed as the proportion of patients achieving:  i) An increase in HOS ADL greater than 9 points 
(minimum detectable change and a clinically important change within an individual)(15) ii) ‘Expectation’ 
HOS ADL (score patients expect to achieve after treatment measured at baseline) iii) Patient Acceptable 
Symptomatic State (PASS) (outcome HOS ADL greater than 87 points)(26)  within the mITT population 
eight months post randomisation. 
Supporting analyses of the primary endpoint included a multi-level mixed-effects model with repeated 
measures of HOS ADL adjusting for baseline HOS ADL, gender, age, time from randomisation, and study 
site (Supporting Analysis A).  The primary analysis was then repeated with: i) additional adjustment for 
HADS, and imaging measures of osteoarthritis (radiographic Kellgren-Lawrence grade) and hip 
morphology (maximum cartilage alpha angle on MRI, centre-edge angle on anteroposterior pelvis 
radiograph) (Supporting Analysis B). ii) the per protocol population (PP) excluding participants with major 
deviations from the trial protocol (Supporting Analysis C). iii) six months post intervention outcomes 
(Supporting Analysis D). Primary analysis was also repeated with the baseline ‘expectation’ HOS ADL as a 
covariate. Participants with available baseline and outcome data were included in these analyses.  
The potential impact of missing data on trial conclusions was considered using multiple imputation 
(missing at random data) and sensitivity analysis (missing not at random data).  Multiple imputation by 
chained equations was performed using the ‘mi impute chained’ command in Stata. A linear regression 
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model was used to impute missing outcomes for the HOS ADL at eight months post randomisation. 
Variables in the imputation model included all covariates in the analysis model (baseline HOS 
(continuous), age (continuous) and gender). In addition, other variables that were thought to be 
predictive of the outcome were included (lateral centre edge angle, maximum alpha angle, Kellgren-
Lawrence grade, and baseline HADS scores). Imputations were run separately by treatment arm and 
based on a predictive mean matching approach, choosing at random one of the five HOS ADL values with 
the closest predicted scores. Missing data in the covariates that were included in the multiple imputation 
model were imputed simultaneously (multiple imputation by chained equation approach). Sensitivity 
analysis was performed using the ‘rctmiss’ command in Stata and scenarios were considered where 
participants with missing data in each arm were assumed to have outcomes that were up to nine points 
worse than when missing at random (Figure S2).  
Secondary PROMs were analysed using a multilevel mixed-effects model, with repeated measures of the 
relevant PROM (collected at 5 and 8 months) nested within participants. The models used data from 
participants with available baseline and at least one follow-up assessment, adjusting for baseline PROM, 
gender, age, study site, and time from randomisation. 
Pre-defined sub-group exploration was performed for the following participant groups: osteoarthritis 
grade (Kellgren-Lawrence 0 versus 1), gender, age (continuous variable), baseline HOS ADL category 
(continuous variable), and FAI type (pincer/cam/mixed). Treatment effects by binary subgroup were 
illustrated with forest plots, showing point estimates, confidence intervals and heterogeneity p-values 
(estimates obtained from interaction models including only the relevant subgroup and randomised 
treatment as covariates). The differential treatment effect for age and baseline HOS ADL (as continuous 
variables) was further explored by adding an interaction term for treatment*age and treatment*baseline 
HOS ADL into the primary analysis model. Linear and non-linear effects (squared and cubic terms) for age 
and baseline HOS ADL were explored.. 
Details on clinical examination, including range of movement and signs of impingement were summarised 
descriptively for each follow-up time points. The trial is registered at ClinicalTrials.gov: NCT01893034. 
14 
 
Patient Involvement: 
A feasibility study included patient questionnaires to determine outcomes they felt were most important, 
treatment preferences, acceptable study design, and anticipated recruitment numbers(12). Study design 
was then based on these findings. A patient representative provided guidance throughout the study 
including an evaluation of the burden of intervention and assessments. Study results will be disseminated 
through publication, presentation at scientific meetings, and at patient and public engagement events 
coordinated by our institution. The results will also be disseminated using social media platforms.  
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Results: 
495 patients were screened across seven orthopaedic centres between 24 May 2013 and 30 September 
2016, of whom 350 (71%) met the study eligibility criteria (Figure 3). 222 (63%) of the 350 eligible patients 
elected to participate and were randomised to arthroscopic surgery or physiotherapy (45% of all patients 
screened). The principal reason for declining participation was a treatment preference for surgery 58 (45%) 
or physiotherapy 33 (26%).  Of the 222 patients enrolled in the trial, 112 were allocated to receive 
arthroscopic surgery and 110 were allocated to receive physiotherapy. Baseline demographic and clinical 
characteristics were well balanced across treatment groups (Table 1). Mean age was 36 years (SD 9.7) and 
there was a higher proportion of females (66%) than males (34%). The primary pathology was isolated cam 
morphology FAI (94%) and at baseline the mean HOS ADL subscale was 65.9 (SD 18.7). 
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Table 1: Baseline Characteristics 
 Physiotherapy 
(n = 110) 
 
Arthroscopic Surgery   
(n = 112) 
  
Total  
(n=222) 
 
    
Left 
Right 
51 (46.4%) 
59 (53.6%) 
45 (40.2%) 
67 (59.8%) 
96   (43.2%) 
126 (56.8%) 
Male 
Female 
37 (33.6%) 
73 (66.4%) 
38 (33.9%) 
74 (66.1%) 
75   (33.8%) 
147 (66.2%) 
 
Age^ 
 
36.0 (SD 9.9) 
Range 18, 60 
n=110 
36.4 (SD 9.6) 
Range 18, 59 
n=112 
36.2 (SD 9.7) 
Range 18, 60 
 
Height (cm)^ 
171.9 (SD 9.2) 
Range 154, 193 
n=107 
170.5 (SD 10.4) 
Range 151, 211 
n=111 
171.2 (SD 9.8) 
Range 151, 211 
 
Weight (kg)^ 
78.6 (SD 14.6) 
Range 53, 117 
n=108 
76.1 (SD 18.7) 
Range 42, 143 
n=109 
77.3 (SD 16.8) 
Range 42, 143 
 
BMI^ 
 
26.6 (SD 4.8) 
Range 18, 41 
n=106 
25.9 (SD 4.8) 
Range 17, 42 
n=109 
26.2 (SD 4.8) 
Range 17, 42 
    
 
Baseline HOS ADL  
 
65.7 (SD 18.9) 
Range 12, 99 
n=110 
66.1 (SD 18.5) 
Range 28, 99 
n=112 
65.9 (SD 18.7) 
Range 12, 99 
    
Cam 104 (94.5%) 104 (92.9%) 208 (93.7%) 
Pincer 0 (0.0%) 1 (0.9%) 1 (0.5%) 
Mixed 6 (5.5%) 7 (6.3%) 13 (5.9%) 
    
Bone Average Alpha Angle 66.8 (SD 11.8) 
Range 43, 93 
n=95 
67.4 (SD 12.5) 
Range 43, 112 
n=94 
67.1 (SD 12.2) 
Range 43, 112 
Bone Maximum Alpha Angle 86.4 (SD 16.9) 
Range 46, 128 
n=95 
85.9 (SD 17.1) 
Range 47, 120 
n=94 
86.1 (SD 17.0) 
Range 46, 128 
Cartilage Average Alpha Angle 67.2 (SD 10.8) 
Range 47, 90 
n=95 
67.4 (SD 11.5) 
Range 46, 110 
n=94 
67.3 (SD 11.1) 
Range 46, 110 
Cartilage Maximum Alpha Angle 86.3 (SD 15.5) 
Range 50, 120 
n=95 
85.6 (SD15.4) 
Range 49, 118 
n=94 
86.0 (SD 15.4) 
Range 49, 120 
Lateral Centre Edge Angle 
 
29.2 (SD 6.7) 
Range 13, 51 
n=105 
28.5 (SD 6.8) 
Range 15, 53 
n=106 
28.8 (SD 6.8) 
Range 13, 53 
    
Kellgren Lawrence Grade    
    KL grade 0 87 (79.1%) 90 (80.4%) 177 (79.7%) 
    KL grade 1 18 (16.4%) 16 (14.3%) 34 (15.3%) 
    No radiograph available 5 (4.5%) 6 (5.4%) 11 (5.0%) 
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In the arthroscopic surgery group, 99 (88%) participants received their allocated treatment. In the 
physiotherapy group, 96 (87%) of patients commenced, and 91 (83%) of patients completed, their 
allocated treatment (Table 2 and Figure 3). Of the 19 patients that did not complete their allocated 
physiotherapy programme, eight withdrew from the study prior to intervention and two withdrew after 
the first session of physiotherapy, three patients were not contactable after randomisation, three 
decided to stop physiotherapy after commencing treatment and subsequently received arthroscopic 
surgery, and three failed to attend any of their physiotherapy appointments.  
133 participants (47 arthroscopic surgery and 86 physiotherapy) commenced treatment within 12 weeks 
of randomisation and were assessed at 8 months post randomisation. Intervention commenced 12 weeks 
or more after randomisation for 62 participants (52 arthroscopic surgery and 10 physiotherapy) and 
outcomes were measured eight months post randomisation and six months post intervention. The 
significant proportion of patients who commenced treatment after 12 weeks reflected increased NHS 
waiting times within the duration of this study. The median time from randomisation to surgery in the 
arthroscopic surgery group was 86 days and from randomisation to the first appointment in the 
physiotherapy group was 44 days (Table 2). 
  
18 
 
Table 2: Details of Participants Commencing Allocated Intervention 
 
Arthroscopic Surgery 
(n=99) 
Physiotherapy 
(n=96)~ 
   
     
Average time from randomisation to surgery or commence physiotherapy 
(days)^ 
86 IQR: 59-132, 
 Range: 5-435 
44  IQR 33-61, 
 Range 14-251 
     
     
Physiotherapy Intervention*:     
     
   Average number of physiotherapy sessions attended^   6 IQR 4-8, 
 Range 1-8 
 
   Average duration of first physiotherapy session (minutes)^   60 IQR 60-60, 
 Range 30-95 
 
   Average length of follow-up physiotherapy sessions (minutes)^ (n=83)   30  IQR 30-30, 
 Range 20-60 
     
     
Surgical Intervention#:     
     
   Labral procedure only$ 9  (9.1%)   
   Femoral osteochondroplasty 66 (66.7%)   
   Acetabular osteochondroplasty (rim-trim) 5  (5.1%)   
   Femoral osteochondroplasty + acetabular osteochondroplasty (rim-trim) 19 (19.2%)   
     
   No labral procedure 4 (4.0%)   
   Labral repair 70 (70.4%)   
   Labral debridement 25 (25.5%)   
     
   No microfracture 90 (90.8%)   
   Microfracture 9 (9.2%)   
     
   Average number of physiotherapy sessions attended 4 IQR 2.5-6, 
 Range 1-14 
  
     
     
   Average operation time^ (n=77) 55  IQR 45-80,
 Range 22-160 
  
     
~Includes five patients that commenced physiotherapy intervention but did not complete the programme. 
^median #frequency and percentage *information available for 88 of 91 patients who completed physiotherapy. 
$Greater degree of osteoarthritis found at arthroscopy than evident preoperatively and no osteochondroplasty performed in 
three patients. In six patients there was no evidence of femoroacetabular impingement on intra-operative assessment. 
IQR: Interquartile Range 
 
  
19 
 
There was complete data for primary analysis on 188 (85%) participants (88 (80%) of individuals 
randomised to physiotherapy and 100 (89%) of individuals randomised to arthroscopic surgery). Reasons 
for exclusion of the 34 participants from the primary analysis were loss to follow up for 7 (3%), complete 
withdrawal from trial for 11 (5%), and incomplete primary end-point data for 16 (7%) (Figure 3). 
Participants in the arthroscopic surgery group had a mean HOS ADL score that was 10.0 points (95% CI 6.4 
to 13.6, p=0.001) higher than participants in the physiotherapy group at eight months post randomisation. 
This mean difference was statistically significant and exceeded the pre-specified minimum clinically 
important difference of nine points, although the lower boundary of the confidence interval was less than 
nine points (Table 3 and Figure 4). Eight month post randomisation HOS ADL scores were higher than 
baseline in 70% (95% CI 60 to 78%) patients allocated to arthroscopic surgery compared with 50% (95% CI 
40 to 60%) patients allocated to physiotherapy. Clinically important improvement within the individual, 
defined as an increase in HOS ADL greater than nine points, was reported in 51% (95% CI 41 to 61%) of 
patients allocated to arthroscopic surgery and 32% (95% CI 22 to 42%) of patients allocated to 
physiotherapy. A Patient Acceptable Symptomatic State (PASS), defined as HOS ADL greater than 87 
points(26), was achieved in 19% (95% CI 11 to 28%) of patients allocated to physiotherapy and 48% (95% 
CI 38% to 58%) of patients allocated to arthroscopic surgery eight months post randomisation. The 
proportion of patients who achieved their ‘expectation’ HOS ADL eight months post randomisation was 
15% (95% CI 23 to 41%) for physiotherapy and 31% (95% CI 9 to 24%) for arthroscopic hip surgery.  
All supporting analyses of the HOS ADL, including the per protocol analysis, and analysis using multiple 
imputation, demonstrated similar results to the primary analysis with slightly increased treatment effects 
that were also  statistically significant (Table 3). Baseline ‘expectation’ HOS ADL was not statistically 
significant when included as a covariable in the primary analysis and did not change the treatment effect. 
The treatment effects were robust even to an extreme missing not at random sensitivity analyses, which 
considered outcomes for those with missing data that were up to nine points worse than expected in the 
primary analysis (Figure S2).  
20 
 
Subgroup exploration of binary variables identified no evidence of a differential treatment effect for gender 
or osteoarthritis grade. The small number of individuals with pincer morphology limited the ability to 
compare outcomes for different FAI type (pincer versus cam versus mixed) (Figure S3). There was a 
suggestion of an interaction between treatment and baseline age, with a decreasing difference in 
treatment effect between arthroscopic surgery and physiotherapy with increasing age (Table S3 and Figure 
S4). Baseline HOS ADL did not appear to influence the differential treatment effect between groups  (Table 
S3 and Figure S5). 
Eight-month post-randomisation secondary PROM scores including HOS Sports subscale, NAHS, OHS, iHOT, 
HAGOS, UCLA, PainDetect, EQ5D and HADS depression score were significantly higher in participants who 
received arthroscopic surgery compared with physiotherapy (p <0.05) (Table 4). However, there was no 
significant difference in the HADS anxiety score between treatment groups (p = 0.184). 
Patients allocated to arthroscopic surgery had a greater range of hip flexion compared with physiotherapy 
eight months post randomisation, although there was no statistically significant difference for other 
movements (Table 5). A smaller proportion of patients allocated to arthroscopic hip surgery reported pain 
on hip flexion at follow-up compared with physiotherapy, as was also found for hip abduction, adduction, 
and FAbER, but not FAdIR (Table 6).   
At eight-month follow up, two patients crossed over to receive arthroscopic surgery on reporting no 
improvement in their symptoms after physiotherapy intervention (in addition to four patients who were 
allocated physiotherapy but received arthroscopic surgery prior to completing their physiotherapy 
programme). A further patient in the physiotherapy group was referred to the chronic pain service. 
Complications occurred in three (3%) patients in the arthroscopic surgery group. Superficial wound 
infection was reported for one patient 12 days after surgery that resolved with oral antibiotics. Injury to 
the lateral cutaneous nerve of the thigh was reported for two patients, that had resolved in one patient at 
eight-month follow-up. No participant had serious adverse events related to the trial intervention or trial 
procedure.
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Table 3: Primary and Supporting Analyses 
 Physiotherapy 
 
Arthroscopic Surgery 
 
Arthroscopic Surgery versus 
Physiotherapy 
  
 Mean Standard 
Deviation 
Number of 
Patients 
Mean Standard 
Deviation 
Number of 
Patients 
Adjusted† 
Treatment 
Effect 
95% 
Confidence 
Intervals 
p-value 
Primary analysis: 
HOS at 8 months post randomisation 
69.2 19.1 88 78.4 19.9 100 10.0 6.4 to 13.6  0.001 
Supporting analysis A: 
Multilevel mixed-effects model* 
-   -   10.5  6.4 to 14.6 <0.001 
Supporting analysis B: 
Additional adjustment^ 
69 19.5 77 80.1 18.7 83 11.7 9.4 to 14.1  0.001 
Supporting analysis C: 
Per protocol population$ 
69.7 18.6 81 80.5 18.9 79 11.9  6.2 to 17.5  0.002 
Supporting analysis D: 
Post intervention analysis% 
69.2 19.3 87 80.4  19.6 91 12.0 7.3 to 16.7  0.001 
Multiple imputation analysis 68  20.2 110 78.4  20.3 112 10.0 5.3 to 14.7  0.004 
All analysis models are adjusted for baseline HOS ADL (continuous), gender, age at randomisation (continuous) and site (using cluster robust standard errors). 
*Multilevel mixed-effects model adjusted for baseline HOS ADL, gender and age at randomisation, time from randomisation (continuous), together with a quadratic term. Participant and 
randomising site are used as random effects. Data measured up to ten months post randomisation included in the analysis. This analysis includes 330 observations from 191 participants. 
^Primary analysis repeated with additional covariates: centre edge angle (continuous), maximum alpha angle (continuous), Kellgren-Lawrence grade (categorical variable with values 0 and 1), 
and HADS score (anxiety and depression subscales (continuous). 
$ Primary analysis repeated for the per protocol population (participants who received their allocated intervention at least eight weeks prior to eight-months post randomisation assessment). 
%Primary analysis repeated substituting the eight month post randomisation HOS ADL with the six month post intervention HOS ADL in patients where the time from randomisation to 
intervention exceeded 12 weeks. 
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Table 4: Secondary PROMs Analysis 
 
 
 Physiotherapy 
Number of participants 
(number of observations) 
Arthroscopic Surgery 
Number of participants 
(number of observations) 
Arthroscopic Surgery versus Physiotherapy 
Adjusted† Treatment effect (95%CI) 
 
p-value† 
HOS Sports subscale1 91 (166) 99 (163) 11.7  (5.8 to 17.6)   <0.001 
OHS1 87 (160) 92 (153) 5.3 (3.2 to 7.5)  <0.001 
NAHS1 78 (139) 91 (147) 11.2 (6.8 to 15.7)  <0.001 
iHOT1 88 (162) 92 (155) 2.0 (1.3 to 2.8)  <0.001 
HAGOS Symptoms1 88 (161) 92 (155) 13.3  (8.1 to 18.6) <0.001 
HAGOS Pain1 88 (161) 92 (154) 12.7  (8.1 to 17.2) <0.001 
HAGOS ADL1 88 (162) 92 (154) 11.6  (6.7 to 16.6) <0.001 
HAGOS Sport1 88 (161) 92 (155) 13.1  (7 to 19.1) <0.001 
HAGOS PA1 88 (162) 91 (153) 14.6  (7.2 to 22)  <0.001 
HAGOS QoL1 88 (162) 91 (154) 13.2  (7.5 to 19)  <0.001 
UCLA1 88 (162) 92 (155) 0.6  (0.1 to 1)    0.01 
PainDetect Score2 62 (101) 61 (93) -2.1  (-4 to -0.2)    0.03 
HADS anxiety2 88 (162) 91 (153) -0.6  (-1.4 to 0.3)   0.18 
HADS depression2 88 (162) 91 (153) -1.3 (-2.2 to -0.4)    0.004 
EQ-5D-3L index1 88 (161) 91 (153) 0.1 (0 to 0.1)   0.003 
EQ-5D-3L VAS1 85 (153) 86 (145) 0.7 (0.3 to 1.2)    0.002 
†Multilevel mixed-effects model for mITT population adjusted for baseline HOS ADL, gender and age at randomisation, time from randomisation (continuous), together with a quadratic term. 
Participant and randomising site are used as random effects. Data measured up to ten months post randomisation included in the analysis. 
1For this PROM, higher values indicate better outcomes. 2For this PROM, lower values indicate better outcomes. 
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Table 5 : Range of Hip Movement at Baseline and Eight Month Post Randomisation Assessment 
 Physiotherapy 
Baseline 
Physiotherapy 
8 Month Assessment 
Arthroscopic Surgery 
Baseline 
Arthroscopic Surgery 
8 Month Assessment 
Difference in ROM 
Adjusted for Baseline 
Statistical 
Significance$ 
Hip Flexion 
95.7 (SD 19.1) 
Range 27, 126 
n=107 
99.7 (SD 17.5) 
Range 25, 130) 
n=85 
96.9 (SD 15.8) 
Range 50, 130 
n=111 
105.8 (SD 16.3) 
Range 40, 138 
n=96 
 4.8 
(95% CI 0.5 to 9.1)  
p=0.03 
 Hip Extension 
17.9 (SD 7.9) 
Range 5, 50 
n=100 
15.7 (SD 8.0) 
Range 0, 46) 
n=83 
18.2 (SD 8.0) 
Range 0, 40 
n=104 
16.8 (SD 7.4) 
Range 0, 45) 
n=96 
 1.6 
(95% CI -0.6 to 3.8)  
p=0.16 
 Hip Abduction 
27.5 (SD 11.9) 
Range 5, 60 
n=107 
29.6 (SD 11.7) 
Range 5, 70 
n=84 
27.1 (SD 12.0) 
Range 5, 80 
n=110 
30.3 (SD 10.6) 
Range 8, 66 
n=96 
 1.0 
(95% CI -2.1 to 4.1)  
p=0.53 
Hip Adduction 
21.6 (SD 7.9) 
Range 5, 44 
n=104 
23.2 (SD 8.9) 
Range 5, 50 
n=84 
20.9 (SD 8.2) 
Range 5, 60 
n=108 
23.9 (SD 8.2) 
Range 9, 45 
n=96 
 1.1 
(95% CI -1.2 to 3.5)  
p=0.35 
 Hip Internal Rotation 
24.0 (SD 11.2) 
Range 5, 55 
n=107 
28.9 (SD 11.2) 
Range 2, 55 
n=84 
24.9 (SD 11.2) 
Range 2, 56 
n=110 
30.8 (SD 10.6) 
Range 5, 69 
n=96 
 1.4 
(95% CI -1.6 to 4.4) 
p=0.37 
 Hip External Rotation 
25.0 (SD 11.8) 
Range 5, 80 
n=107 
27.4 (SD 9.7) 
Range 8, 70 
n=84 
26.2 (SD 10.6) 
Range 7, 80 
n=110 
27.0 (SD 8.9) 
Range 10, 50 
n=96 
-1.1 
(95% CI -3.6 to 1.4)  
p=0.38 
$ Wilcoxon Rank-Sum Test  
ROM: Range of Movement, SD: Standard Deviation, CI: Confidence Interval 
       
       
       
       
  
 
 
     
       
Table 6 – Hip Assessment at Baseline and Eight Month Post Randomisation 
 Physiotherapy 
Baseline^ 
Physiotherapy 
8 Month Assessment^ 
Arthroscopic Surgery 
Baseline^ 
Arthroscopic Surgery 
8 Month Assessment^ 
Statistical 
Significance$ 
 
Pain on Flexion Yes 77 (70.0%) 56 (50.9%) 80 (71.4%) 46 (41.1%) 
p=0.01 
 
No 31 (28.2%) 29 (26.4%) 31 (27.7%) 51 (45.5%)  
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Not Available 2 (1.8%) 25 (22.7%) 1 (0.9%) 15 (13.4%)  
Pain on 
Extension 
Yes 44 (40%) 24 (21.8%) 41 (36.6%) 18 (16.1%) 
p=0.10 
 
No 61 (55.5%) 59 (53.6%) 67 (59.8%) 79 (70.5%)  
Not Available 5 (4.5%) 27 (24.5%) 4 (3.6%) 15 (13.4%)  
Pain on 
Abduction 
Yes 72 (65.5%) 48 (43.6%) 74 (66.1%) 41 (36.6%) 
p=0.05 
 
No 36 (32.7%) 36 (32.7%) 38 (33.9%) 56 (50.0%)  
Not Available 2 (1.8%) 26 (23.6%) 0 (0%) 15 (13.4%)  
Pain on 
Adduction 
Yes 51 (46.4%) 39 (35.5%) 61 (54.5%) 30 (26.8%) 
p=0.03 
 
No 55 (50.0%) 45 (40.9%) 50 (44.6%) 67 (59.8%)  
Not Available 4 (3.6%) 26 (23.6%) 1 (0.9%) 15 (13.4%)  
Pain on 
Internal Rotation 
Yes 78 (70.9%) 47 (42.7%) 77 (68.8%) 44 (39.3%) 
p=0.16 
 
No 30 (27.3%) 37 (33.6%) 34 (30.4%) 53 (47.3%)  
Not Available 2 (1.8%) 26 (23.6%) 1 (0.9%) 15 (13.4%)  
Pain on 
External Rotation 
Yes 55 (50.0%) 33 (30.0%) 50 (44.6%) 30 (26.8%) 
p=0.24 
 
No 53 (48.2%) 51 (46.4%) 61 (54.5%) 67 (59.8%)  
Not Available 2 (1.8%) 26 (23.6%) 1 (0.9%) 15 (13.4%)  
FAdIR Test Positive 95 (86.4%) 66 (60.0%) 103 (92%) 70 (62.5%) 
p=0.38 
 
Negative 11 (10.0%) 18 (16.4%) 9 (8.0%) 26 (23.2%)  
Not Available 4 (3.6%) 26 (23.6%) 0 (0%) 16 (14.3%)  
FAbER Test Positive 89 (80.9%) 52 (47.3%) 91 (81.3%) 42 (37.5%) 
p=0.02 
 
Negative 18 (16.4%) 32 (29.1%) 21 (18.8%) 54 (48.2%)  
Not Available 3 (2.7%) 26 (23.6%) 0 (0%) 16 (14.3%)  
FAdIR Test = Pain on Flexion, Adduction, Internal Rotation. FAbER Test = Pain on Flexion, Abduction, External Rotation. ^Frequency (Percentage) 
$Chi Square Test for association between outcomes eight months post randomisation 
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Discussion: 
Principal Findings: 
The results of this trial demonstrate that patients with symptomatic FAI experience a greater 
improvement in symptoms with arthroscopic hip surgery compared with physiotherapy and activity 
modification eight months post randomisation. The 10 point mean difference in HOS ADL between 
groups is greater than the pre-specified minimum clinically important difference of nine points, however, 
the lower boundary of the confidence interval is less than this nine point threshold for clinical 
importance. In this cohort, the difference in HOS ADL between treatment groups is expected to lie 
between 6.4 and 13.6 points in favour of arthroscopy. 
Within the individual, 51% of patients randomised to arthroscopic hip surgery and 32% of patients 
randomised to physiotherapy reported an improvement in HOS ADL that exceeded nine points (minimum 
detectable change and a clinically important change within an individual). In addition, 48% of patients 
randomised to arthroscopic hip surgery and 19% of patients randomised to physiotherapy achieved the 
PASS after treatment. 
Blinded clinical assessments revealed a greater improvement in the range of hip flexion and associated 
discomfort in patients allocated to arthroscopic surgery compared with physiotherapy. Additional patient 
reported outcome measures also indicated improved outcomes in patients randomised to arthroscopic 
hip surgery.  
Comparison with Other Studies: 
Two other randomised controlled trials comparing physiotherapy rehabilitation with arthroscopic surgery 
for symptomatic FAI were published in 2018 with comparable protocols to this study. Mansell et al. did not 
find a difference between arthroscopic surgery and physiotherapy at any time point up to two-year follow-
up, although there was a 70% cross-over from allocated physiotherapy to arthroscopic surgery(8). Griffin 
et al. concluded that arthroscopic surgery was superior to best conservative care at improving symptoms 
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at 12-month follow-up, but not cost-effective(27). Contrary to our study, they did not find differences 
between treatment groups for secondary outcome measures of general health-related quality of life (EQ-
5D and SF-12). Arthroscopic surgery and physiotherapy are safe and the low complication rates found in 
this trial are consistent with other studies(7, 28). The age and gender of patients recruited reflected 
national trends in the provision of arthroscopic hip surgery(10). 
Strengths and Limitations: 
Surgery was performed by consultant orthopaedic surgeons with a specialist interest in the young adult 
hip, which reflects the provision of hip arthroscopy in the NHS and recommendations from the National 
Institute for Health and Care Excellence (NICE). Participating centres consisted of five District General 
Hospitals and two University Teaching Hospitals. The delivery of care by surgeons performing a high 
volume of arthroscopic hip procedures ensured they are beyond the steep learning curve for this surgery, 
and the risk of complications is higher for surgeons performing a low volume of procedure(29, 30). A 
limitation of our study is that the majority of patients were recruited from the coordinating centre, 
however, the treatment effect was consistent for centres recruiting more than 20 patients (Figure S3). 
Physiotherapy was delivered by physiotherapists of different seniority trained in the study protocol with 
a maximum of eight sessions. There is very little evidence to guide the development of an optimal 
physiotherapy protocol. It could be suggested that a greater number and frequency of physiotherapy 
sessions with only senior specialist physiotherapists may improve outcomes. Our aim was to compare 
arthroscopic hip surgery with a physiotherapy intervention that is deliverable within the constraints of 
NHS resources to ensure generalisability and restrict excess treatment costs. Standard commissioning in 
the NHS limits physiotherapy provision to approximately six sessions of individual physiotherapy and we 
offered a maximum of eight sessions. 
Patients in both treatment groups received physiotherapy, either as their primary intervention, or as 
post-surgical rehabilitation. It is important to emphasise the difference in these regimes. The focus of 
physiotherapy for the treatment of FAI syndrome (randomised study intervention) was to improve pain 
and function. The principal elements of our programme started with activity and movement modification, 
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followed by muscle strengthening and segmental stabilisation, and finally optimisation of functional 
movements with sensory motor training and return to activity according to patient goals. This 
physiotherapy package was delivered over a median of six sessions. The focus of physiotherapy post 
arthroscopic surgery was to maintain range of movement and guide return to activity. Patients were 
advised to commence active range of movement and isometric exercises the day following surgery, 
progressing to stretches and static bicycle exercise (no resistance) within a week. Strengthening exercises 
and low impact activities were introduced after three weeks, usually under physiotherapist guidance, and 
impact exercise was permitted after six weeks with sport-specific rehabilitation when appropriate. This 
physiotherapy package was delivered over a median of four sessions. 
The clinical significance of an improved range of hip flexion in patients allocated to arthroscopic surgery 
compared with physiotherapy is not known. A cohort study of patients receiving arthroscopic hip surgery 
found that hip flexion was the only movement associated with improved patient reported outcome 
measures(31). A possible explanation is the functional importance of this movement during everyday 
activities such as sitting or climbing stairs, when pain is frequently experienced with FAI syndrome. 
Despite the limitation of performing multiple statistical tests, our results also suggest less pain on hip 
movements in patients allocated to arthroscopic hip surgery compared with physiotherapy. 
Overall, 70% of patients randomised to arthroscopy and 50% of patients randomised to physiotherapy 
reported an improvement in HOS ADL, however, only half the participants randomised to arthroscopy 
reported an improvement in HOS ADL exceeding nine points or achieved the PASS. A limitation of 
reported minimally clinically important differences between groups or changes within an individual is 
that they are specific to the cohort and methodology researchers used to calculate values. We pre-
specified an HOS ADL of nine points as the minimum clinically important difference between groups(15). 
We also used this value to explore the proportion of patients that achieved a clinically important change 
in HOS ADL. Since developing the study protocol, the smallest detectable change in HOS ADL within an 
individual has been calculated as nine points, and the minimum clinically important change in HOS ADL 
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within an individual as five points(36). This finding supports our use of a nine-point threshold to 
represent both a clinically important difference between groups and change within an individual.  
Whilst arthroscopic hip surgery appears superior to physiotherapy, patients must be informed of the 
potential risks and benefits of surgery, including the risk of no improvement.  Up to a half of patients will 
not achieve a clinically important improvement after surgery, hence accurate patient selection is critical 
to optimising treatment outcomes. Increasing patient age, higher pre-operative patient-reported scores, 
and the presence of osteoarthritis have been identified as having a negative impact on outcome in cohort 
studies of arthroscopic hip surgery(32-35). 
Exploration of subgroups suggested that older patients may gain less benefit from arthroscopic surgery 
compared with physiotherapy, however, there was large variation in HOS ADL outcome scores across 
different ages. Further exploration in a larger population is required to determine the effect of age on 
outcomes.  Cohort studies also report that hip arthroscopic surgery is less effective with increasing 
age(32, 33), however, older patients also experience significant improvements in symptoms(32).  
Patients with established osteoarthritis defined as patients with ‘osteophytes and possible joint space 
width narrowing’ (Kellgren Lawrence 2) or more severe disease were excluded from the study. Patients 
with ‘possible osteophytes and doubtful narrowing of joint space’ (Kellgren-Lawrence 1) were included. 
Cohort studies suggest that osteoarthritis is only detrimental to outcomes once there is established loss 
of joint space width(34). In our exploratory evaluation of subgroups we did not detect a difference in 
treatment effect between individuals with Kellgren-Lawrence 1 disease and those with no radiographic 
osteoarthritis (Kellgren-Lawrence 0), although our study was not powered for this calculation. 
We were unable to explore whether the presence of cam, pincer, or mixed morphology influences 
treatment effect due to the small number of patients with pincer impingement. The relative proportion 
of patients with each FAI type in this cohort reflects the general population, but the results of this study 
may not be generalisable to pincer and mixed morphology FAI. Exploratory analysis within the study 
population did not find an association between outcome and any morphological hip measurement, 
including the magnitude of cam or pincer morphology and an interaction term.  
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The exclusion of patients with dysplasia and osteoarthritis is a potential limitation of the study given 
these patients may also benefit from arthroscopic hip surgery, however, our inclusion criteria reflect 
current evidence-based clinical practice(11, 12). We anticipate that advances in imaging will enhance our 
ability to identify patients most likely to benefit from intervention through enhanced diagnosis of 
osteoarthritis and dynamic assessment of hip morphology. In this study, intra-operatively three patients 
were found to have more advanced osteoarthritis than was appreciated preoperatively, and six patients 
were not found to impinge within a functional range of movement despite the preoperative diagnosis of 
cam morphology. The planned osteochondroplasty procedure was therefore not performed. Total hip 
replacement may have been more appropriate in the patients with osteoarthritis. 
Psychological factors are likely to influence outcomes from FAI treatment(36) as found for joint 
arthroplasty(37). Patient expectation was not found to influence treatment effect in this study, but further 
exploration into the effect of baseline depression and anxiety on outcomes may be of value given cohort 
studies have demonstrated that they influence outcome(36). The most frequent reason for declining 
participation was preference for surgery. Four patients randomised to physiotherapy underwent surgery 
prior to collection of the primary outcome measure. Our results may in part reflect a nocebo effect of 
physiotherapy and placebo effect of surgery. The placebo effect has been shown to be large in surgical 
trials of arthroscopic shoulder decompression(38) and arthroscopic meniscectomy(39). Our blinded clinical 
assessments offer reassurance of a differential treatment effect between groups. An ongoing trial 
comparing osteochondroplasty with arthroscopic lavage for FAI syndrome may offer further insight into 
the efficacy of surgical treatment(40). 
Median time to treatment post randomisation was 44 days for physiotherapy and 86 days for arthroscopic 
surgery. Comparing operative and non-operative management is challenging given surgical care is usually 
delivered at a single timepoint whereas physiotherapy takes place over weeks or months. The longer 
waiting times for surgery may influence results, however, this is a pragmatic trial and the care delivered 
accurately reflects current practice in NHS settings. Intention to treat rather than post-intervention analysis 
was selected as the primary outcome because whereas groups are balanced at the time of randomisation 
(a requirement for inferring a causal relationship between intervention and outcome), this may not be true 
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at any other timepoint. We also performed a post-intervention analysis (Supporting Analysis D), which 
revealed a comparable treatment effect to the mITT analysis (Table 3). There were dropouts in both 
treatment groups, and although the study remained adequately powered, baseline scores were slightly 
lower in the physiotherapy group (Table S2). Nevertheless, our primary analysis adjusts for prognostic 
factors and the treatment effect was robust to different assumptions regarding missing data (missing at 
random and missing not at random) in our sensitivity analysis (Figure S2).  
This trial does not capture patients with minimally symptomatic FAI, who are typically diagnosed and 
treated in primary care. Instead it provides guidance for the treatment of patients who are referred to 
secondary or tertiary care with more severe or prolonged symptoms. Given the potential complications of 
surgery and observed clinical improvement with physiotherapy and activity modification, we currently 
recommend this intervention as first-line treatment. If symptoms continue then the likelihood of symptom 
improvement with arthroscopic hip surgery should be given consideration. 
Conclusions and Policy Implications: 
The results of this study suggest that patients with symptomatic FAI referred to secondary or tertiary care 
achieve a greater improvement in patient reported outcomes with arthroscopic hip surgery compared 
with non-operative measures. However, further research is required to identify patients most likely to 
benefit from intervention. The evaluation of treatment cost-effectiveness and disease-modifying 
potential with long-term follow-up of this cohort will further guide treatment and commissioning 
decisions.  
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corresponding author. Consent was not obtained for data sharing but the presented data is anonymised 
and the risk of identification is low. 
Transparency:  
The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study 
being reported; that no important aspects of the study have been omitted; and that any discrepancies 
from the study as planned have been explained. 
 
  
34 
 
References: 
1. Agricola R, Waarsing JH, Arden NK, Carr AJ, Bierma-Zeinstra SM, Thomas GE, et al. Cam impingement 
of the hip: a risk factor for hip osteoarthritis. Nat Rev Rheumatol. 2013;9(10):630-4. 
2. Clohisy JC, Dobson MA, Robison JF, Warth LC, Zheng J, Liu SS, et al. Radiographic structural 
abnormalities associated with premature, natural hip-joint failure. J Bone Joint Surg Am. 2011;93 Suppl 2:3-9. 
3. Ganz R, Leunig M, Leunig-Ganz K, Harris WH. The etiology of osteoarthritis of the hip: an integrated 
mechanical concept. Clin Orthop Relat Res. 2008;466(2):264-72. 
4. Frank JM, Harris JD, Erickson BJ, Slikker W, 3rd, Bush-Joseph CA, Salata MJ, et al. Prevalence of 
Femoroacetabular Impingement Imaging Findings in Asymptomatic Volunteers: A Systematic Review. 
Arthroscopy. 2015;31(6):1199-204. 
5. Khanna V, Caragianis A, Diprimio G, Rakhra K, Beaule PE. Incidence of hip pain in a prospective cohort 
of asymptomatic volunteers: is the cam deformity a risk factor for hip pain? Am J Sports Med. 2014;42(4):793-
7. 
6. Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. Lancet. 
2015;386(9991):376-87. 
7. Papavasiliou AV, Bardakos NV. Complications of arthroscopic surgery of the hip. Bone Joint Res. 
2012;1(7):131-44. 
8. Mansell NS, Rhon DI, Meyer J, Slevin JM, Marchant BG. Arthroscopic Surgery or Physical Therapy for 
Patients With Femoroacetabular Impingement Syndrome: A Randomized Controlled Trial With 2-Year Follow-
up. Am J Sports Med. 2018;46(6):1306-14. 
9. Maradit Kremers H, Schilz SR, Van Houten HK, Herrin J, Koenig KM, Bozic KJ, et al. Trends in Utilization 
and Outcomes of Hip Arthroscopy in the United States Between 2005 and 2013. J Arthroplasty. 2017;32(3):750-
5. 
10. Palmer AJ, Malak TT, Broomfield J, Holton J, Majkowski L, Thomas GE, et al. Past and projected temporal 
trends in arthroscopic hip surgery in England between 2002 and 2013. BMJ Open Sport Exerc Med. 
2016;2(1):e000082. 
11. Palmer AJ, Ayyar-Gupta V, Dutton SJ, Rombach I, Cooper CD, Pollard TC, et al. Protocol for the 
Femoroacetabular Impingement Trial (FAIT): a multi-centre randomised controlled trial comparing surgical and 
non-surgical management of femoroacetabular impingement. Bone Joint Res. 2014;3(11):321-7. 
12. Palmer AJ, Thomas GE, Pollard TC, Rombach I, Taylor A, Arden N, et al. The feasibility of performing a 
randomised controlled trial for femoroacetabular impingement surgery. Bone Joint Res. 2013;2(2):33-40. 
13. Griffin DR, Dickenson EJ, O'Donnell J, Agricola R, Awan T, Beck M, et al. The Warwick Agreement on 
femoroacetabular impingement syndrome (FAI syndrome): an international consensus statement. Br J Sports 
Med. 2016;50(19):1169-76. 
14. Wall PD, Fernandez M, Griffin DR, Foster NE. Nonoperative treatment for femoroacetabular 
impingement: a systematic review of the literature. PM R. 2013;5(5):418-26. 
15. Martin RL, Philippon MJ. Evidence of reliability and responsiveness for the hip outcome score. 
Arthroscopy. 2008;24(6):676-82. 
16. Christensen CP, Althausen PL, Mittleman MA, Lee JA, McCarthy JC. The nonarthritic hip score: reliable 
and validated. Clin Orthop Relat Res. 2003(406):75-83. 
17. Thorborg K, Roos EM, Bartels EM, Petersen J, Holmich P. Validity, reliability and responsiveness of 
patient-reported outcome questionnaires when assessing hip and groin disability: a systematic review. Br J 
Sports Med. 2010;44(16):1186-96. 
18. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total 
knee replacement. J Bone Joint Surg Br. 1998;80(1):63-9. 
19. Mohtadi NG, Griffin DR, Pedersen ME, Chan D, Safran MR, Parsons N, et al. The Development and 
validation of a self-administered quality-of-life outcome measure for young, active patients with symptomatic 
hip disease: the International Hip Outcome Tool (iHOT-33). Arthroscopy. 2012;28(5):595-605; quiz 6-10 e1. 
20. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 
1990;16(3):199-208. 
21. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify 
neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-20. 
22. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. 
23. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-
502. 
35 
 
24. Palmer A, Fernquest S, Gimpel M, Birchall R, Judge A, Broomfield J, et al. Physical activity during 
adolescence and the development of cam morphology: a cross-sectional cohort study of 210 individuals. Br J 
Sports Med. 2018;52(9):601-10. 
25. Domb BG, Stake CE, Botser IB, Jackson TJ. Surgical dislocation of the hip versus arthroscopic treatment 
of femoroacetabular impingement: a prospective matched-pair study with average 2-year follow-up. 
Arthroscopy. 2013;29(9):1506-13. 
26. Chahal J, Van Thiel GS, Mather RC, 3rd, Lee S, Song SH, Davis AM, et al. The Patient Acceptable 
Symptomatic State for the Modified Harris Hip Score and Hip Outcome Score Among Patients Undergoing 
Surgical Treatment for Femoroacetabular Impingement. Am J Sports Med. 2015;43(8):1844-9. 
27. Griffin DR, Dickenson EJ, Wall PDH, Achana F, Donovan JL, Griffin J, et al. Hip arthroscopy versus best 
conservative care for the treatment of femoroacetabular impingement syndrome (UK FASHIoN): a multicentre 
randomised controlled trial. Lancet. 2018;391(10136):2225-35. 
28. Nakano N, Lisenda L, Jones TL, Loveday DT, Khanduja V. Complications following arthroscopic surgery 
of the hip: a systematic review of 36 761 cases. Bone Joint J. 2017;99-B(12):1577-83. 
29. Hoppe DJ, de Sa D, Simunovic N, Bhandari M, Safran MR, Larson CM, et al. The learning curve for hip 
arthroscopy: a systematic review. Arthroscopy. 2014;30(3):389-97. 
30. Ravi B, Jenkinson R, Austin PC, Croxford R, Wasserstein D, Escott B, et al. Relation between surgeon 
volume and risk of complications after total hip arthroplasty: propensity score matched cohort study. BMJ. 
2014;348:g3284. 
31. Kemp JL, Makdissi M, Schache AG, Finch CF, Pritchard MG, Crossley KM. Is quality of life following hip 
arthroscopy in patients with chondrolabral pathology associated with impairments in hip strength or range of 
motion? Knee Surg Sports Traumatol Arthrosc. 2016;24(12):3955-61. 
32. Bryan AJ, Krych AJ, Pareek A, Reardon PJ, Berardelli R, Levy BA. Are Short-term Outcomes of Hip 
Arthroscopy in Patients 55 Years and Older Inferior to Those in Younger Patients? Am J Sports Med. 
2016;44(10):2526-30. 
33. Cvetanovich GL, Weber AE, Kuhns BD, Alter J, Harris JD, Mather RC, 3rd, et al. Hip Arthroscopic Surgery 
for Femoroacetabular Impingement With Capsular Management: Factors Associated With Achieving Clinically 
Significant Outcomes. Am J Sports Med. 2018;46(2):288-96. 
34. Degen RM, Nawabi DH, Bedi A, Kelly BT. Radiographic predictors of femoroacetabular impingement 
treatment outcomes. Knee Surg Sports Traumatol Arthrosc. 2017;25(1):36-44. 
35. Nwachukwu BU, Fields K, Chang B, Nawabi DH, Kelly BT, Ranawat AS. Preoperative Outcome Scores Are 
Predictive of Achieving the Minimal Clinically Important Difference After Arthroscopic Treatment of 
Femoroacetabular Impingement. Am J Sports Med. 2017;45(3):612-9. 
36. Jacobs CA, Burnham JM, Jochimsen KN, Molina Dt, Hamilton DA, Duncan ST. Preoperative Symptoms in 
Femoroacetabular Impingement Patients Are More Related to Mental Health Scores Than the Severity of Labral 
Tear or Magnitude of Bony Deformity. J Arthroplasty. 2017;32(12):3603-6. 
37. Schwartz FH, Lange J. Factors That Affect Outcome Following Total Joint Arthroplasty: a Review of the 
Recent Literature. Curr Rev Musculoskelet Med. 2017;10(3):346-55. 
38. Beard DJ, Rees JL, Cook JA, Rombach I, Cooper C, Merritt N, et al. Arthroscopic subacromial 
decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-
controlled, three-group, randomised surgical trial. Lancet. 2018;391(10118):329-38. 
39. Sihvonen R, Paavola M, Malmivaara A, Itala A, Joukainen A, Nurmi H, et al. Arthroscopic partial 
meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369(26):2515-24. 
40. Investigators F. A multi-centre randomized controlled trial comparing arthroscopic osteochondroplasty 
and lavage with arthroscopic lavage alone on patient important outcomes and quality of life in the treatment of 
young adult (18-50) femoroacetabular impingement. BMC Musculoskelet Disord. 2015;16:64. 
  
36 
 
Figure Legends: 
 
Figure 1. Anteroposterior radiographs demonstrating a) normal morphology b) cam morphology, and c) 
pincer morphology. Bone outlined in yellow represents abnormal morphology that predisposes to FAI, 
and is excised with a burr during arthroscopic surgery to prevent impingement. 
 
Figure 2: Right hip coronal MRI of trial participant randomised to surgery: (A) Baseline image 
demonstrating cam morphology (white arrow). (B) Six months post hip arthroscopy with restoration of 
the normal concavity at the femoral head-neck junction by burring away the cam lesion (white arrow). 
This procedure prevents abutment of the femoral head-neck junction against the acetabular rim during 
a functional range of movement. 
 
Figure 3: CONSORT Diagram 
 
Figure 4: Box and Whisker Plot for HOS ADL at baseline and eight months post randomisation follow up 
(mITT). 
 
Print Abstract: 
Study Questions: Is arthroscopic hip surgery superior to physiotherapy and activity modification for 
improving patient reported outcome measures in patients with symptomatic femoroacetabular 
impingement (FAI)? 
Methods: The Femoroacetabular Impingement Trial (FAIT) is a two-group parallel, assessor-blinded, 
pragmatic randomised controlled study in secondary and tertiary care centres across seven NHS England 
37 
 
sites. 222 participants aged 18 to 60 years with symptomatic FAI confirmed clinically and radiologically 
were randomised (1:1) to receive arthroscopic hip surgery (n = 112) or physiotherapy (n = 110). Exclusion 
criteria included previous surgery, completion of a physiotherapy programme targeting FAI within the 
preceding 12 months, established osteoarthritis, and hip dysplasia. Participants in the physiotherapy 
group received an individualised goal-based programme with emphasis on improving core stability and 
movement control. Up to eight physiotherapy sessions were delivered over five months. Participants in 
the arthroscopic hip surgery group received surgery to excise the bone that impinged during hip 
movements, followed by routine post-operative care. The primary outcome measure was the Hip 
Outcome Score Activities of Daily Living (HOS ADL) at eight months post-randomisation with a pre-
specified minimum clinically important difference of nine points. 
Study Answer: At eight months post-randomisation, mean HOS ADL was 10.0 points higher in the 
arthroscopic hip surgery group compared with the physiotherapy and activity modification group (95% CI 
6.4 to 13.6, p<0.001). Limitations include an overall drop-out rate of 15%, however, study conclusions 
were unchanged after sensitivity analyses for missing data. 
What This Study Adds: The results suggest that arthroscopic hip surgery is superior to physiotherapy and 
activity modification at improving patient reported outcome measures in patients referred to secondary 
or tertiary care with symptomatic FAI. 
Trial Registration: ClinicalTrials.gov: NCT01893034. 
Funding: Arthritis Research UK and National Institute for Health Research (NIHR) Oxford Biomedical 
Research Centre (BRC). 
Conflicts of Interest: None declared. 
Data Sharing: Available on request. 
Figure Legend: Graphs demonstrating the direction and magnitude of change in HOS ADL between 
baseline and eight months post randomisation for each participant. 
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